SLNO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SLNO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Soleno Therapeutics's Issuance of Debt for the three months ended in Jun. 2024 was $0.00 Mil.
Soleno Therapeutics's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.
The historical data trend for Soleno Therapeutics's Issuance of Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soleno Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Issuance of Debt | Get a 7-Day Free Trial | - | - | - | - | - |
Soleno Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Issuance of Debt | Get a 7-Day Free Trial | - | - | - | - | - |
Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.
Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Soleno Therapeutics's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Vivo Opportunity Fund Holdings, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Bhatnagar Anish | director, officer: See Remarks | 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065 |
Kristen Yen | officer: See Remarks | 3 TWIN DOLPHIN DRIVE, SUITE 160, REDWOOD CITY CA 94065 |
Patricia C Hirano | officer: See Remarks | 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065 |
James H Mackaness | officer: Chief Financial Officer | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Vivo Opportunity, Llc | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Abingworth Bioventures Vii Lp | 10 percent owner | PRINCES HOUSE, 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Matthew Pauls | director | 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Llp Abingworth | 10 percent owner | 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Jack W Schuler | 10 percent owner | 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045 |
Carlyle Holdings I L.p. | 10 percent owner | C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
Carlyle Holdings I Gp Sub L.l.c. | 10 percent owner | C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
From GuruFocus
By Marketwired • 11-06-2023
By Marketwired • 08-19-2024
By Marketwired • 05-03-2024
By Marketwired • 08-15-2024
By GuruFocus Research • 12-14-2023
By GuruFocus Research • 04-04-2024
By GuruFocus Research • 09-12-2024
By GuruFocus Research • 04-04-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 06-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.